RARA CRAFT DATABASE for FDA Medical Devices
510(k)K190372

FDA DEVICE FACTS

Aveta System

Meditrina, Inc.

FDA-sourced product information for medical-device development research. Use the official FDA sources at the end of this page when the original public document wording is needed.医療機器開発の調査用に、FDA の公開情報から取った製品情報を示しています。公開文書の原文が必要なときは、このページの最後にある FDA の公式な出典をご覧ください。

DECISION DATEMay 16, 2019PRODUCT CODEHIH

Indications for use

Com parison of Indications for Use Device Indications For Use Aveta System (Subject Device) The Aveta Diagnostic and Therapeutic Hysteroscopy System is intended for intrauterine use by trained gynecologists to permit viewing of the cervical canal and the uterine cavity, provide liquid distension of the uterus and monitor the volume differential between the irrigation fluid flowing into and out of the uterus during diagnostic and surgical procedures to resect and remove tissue such as submucous myomas, endometrial polyps and retained products of conception. Predicate System Component: Truclear™ M orcellator System and Truclear™ Morcellators (K152143) For intrauterine use by trained gynecologists to hysteroscopically resect and remove tissue such as submucous myomas, endometrial polyps and retained products of conception. Predicate System Component: Hysteroscopic Fluid Management System (K123732) To provide liquid distension of the uterus for diagnostic and operative hysteroscopy, and to monitor the volume differential between the irrigation fluid flowing into and out of the uterus. Predicate System Component: Truclear™ Operative Hysteroscope 5C and Sheath 5C (K132015) To permit viewing of the cervical canal and uterine cavity for the purpose of performing diagnostic and surgical procedures. Although the subject device does not have identical indications compared to the individual predicate devices, the subject device has the same general intended use as each of the respective predicate components: 1) to permit viewing of the cervical canal and the uterine cavity during diagnostic and operative procedures, 2) to provide liquid distension of the uterus and monitor fluid volume differential, and 3) to resect and remove tissue such as submucous myomas, endometrial polyps, and retained products of conception. When comparing each component function of the subject device to the indications of the respective predicate components, the subject and predicate devices have the same intended use. Meditrina, Inc. Aveta System

See the full product information製品情報をすべて見るには

Device description, AI/software, PCCP, evaluation and limitations are available with an account: seven days of full access after free registration, then with the paid plan.機器の説明、AI・ソフトウェア、PCCP、評価、制限事項は、アカウントでご覧いただけます。無料登録から 7 日間はすべて利用でき、その後は有料プランでご利用いただけます。

Start free 7-day access7日間無料で利用するLog inログイン

OFFICIAL FDA SOURCES

FDA Record and Public Document Status

Record and document link states are stored separately.FDA Record と公開文書のリンクの状態は、別々に記録しています。

Information reviewed:情報の確認日: August 25, 2026